Brown Advisory’s Alaunos Therapeutics TCRT Stock Holding History

Brown Advisory’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-578	Closed	-$334K	–	1247
2019 Q1	$334K	Hold	578	–	–	﹤0.01%	1095
2018 Q4	$162K	Sell	578 -506	-47%	-$200K	﹤0.01%	1194
2018 Q3	$521K	Hold	1,084	–	–	﹤0.01%	986
2018 Q2	$491K	Hold	1,084	–	–	﹤0.01%	978
2018 Q1	$638K	Sell	1,084 -359	-25%	-$224K	﹤0.01%	765
2017 Q4	$896K	Hold	1,443	–	–	﹤0.01%	710
2017 Q3	$1.33M	Hold	1,443	–	–	﹤0.01%	604
2017 Q2	$1.35M	Hold	1,443	–	–	﹤0.01%	612
2017 Q1	$1.37M	Buy	1,443 +1,084	+302%	+$1.01M	﹤0.01%	570
2016 Q4	$288K	Sell	359 -1,057	-75%	-$953K	﹤0.01%	940
2016 Q3	$1.2M	Hold	1,416	–	–	﹤0.01%	582
2016 Q2	$1.17M	Buy	+1,416	New	+$1.54M	﹤0.01%	575

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Brown Advisory's TCRT Position: Q2 2019 in Review

Brown Advisory sold out of Alaunos Therapeutics (TCRT) in Q2 2019, closing a stake of 578 shares — an estimated $334K sold.

Brown Advisory first reported a position in TCRT in Q2 2016 and held it in 12 quarters. The position peaked at $1.37M in Q1 2017. 140 funds tracked by Wall St. Rank hold TCRT as of Q2 2019.

Brown Advisory reported no remaining Alaunos Therapeutics position as of Q2 2019 after selling out during the quarter.
Brown Advisory sold 578 Alaunos Therapeutics shares in Q2 2019, an estimated $334K.
Brown Advisory first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 12 quarters.
Brown Advisory's Alaunos Therapeutics position peaked at $1.37M in Q1 2017.
140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2019.

Based on Brown Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.